SWITZERLAND – Consortium of investors raise CHF 17m for Vivendy
BioMedInvest AG I, LSP Life Sciences Partners and TVM Capital closed a CHF 17m series-A round for Vivendy Therapeutics Ltd., a bio-pharmaceutical company located in Basel, Switzerland. Vivendy is a pharmaceutical start-up company that is developing an enzyme replacement therapy (ERT) for Morbus Morquio (Mucopolysaccharidosis (MPS) IVA), a rare lysosomal storage disease. It was founded in 2006 as a spin-off from Inotech Biotechnologies AG.
More on Early-stage
Gorillas raises circa USD 1bn in Delivery Hero-led Series C
New funding comes just seven months after a Series B, with the company doubling in value
French mega-rounds shoot up in 2021
France has already seen as many rounds of EUR 100m and above than in 2019 and 2020 combined, Unquote Data shows
L Catterton et al. in EUR 100m round for SellerX
SellerX has already raised amost EUR 250m in debt and equity in its 12 months since inception
Mega-rounds fuel record H1 for venture and growth
Largest rounds inked in the first six months of 2021 read like a veritable Who's Who of European fintech heavyweights
Latest News
Verdane scores 5x MOIC in partial exit of Inriver to THL
Majority investment from THL Partners sees Verdane retain a minority stake in the Swedish company
CVC to buy sports nutrition specialist The Quality Group
GP to acquire majority stake via Fund VIII; German group’s founders to reinvest in the deal
DBAG to target EUR 1.3bn-EUR 1.5bn for new buyout fund next year
German GP’s new vehicle will be slightly larger than its predecessor, which is set to complete deployment in two years
Alcedo heads for June final close for Fund V
Italian GP has received EUR 230m in commitments to date for Fund V against a EUR 250m hard-cap